Senores Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Senores Pharmaceuticals has been growing earnings at an average annual rate of 66.4%, while the Pharmaceuticals industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 68.2% per year. Senores Pharmaceuticals's return on equity is 7.2%, and it has net margins of 14%.
Key information
66.40%
Earnings growth rate
42.31%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | 68.16% |
| Return on equity | 7.18% |
| Net Margin | 14.03% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Senores Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 4,175 | 586 | 604 | 0 |
| 31 Dec 24 | 3,865 | 567 | 648 | 0 |
| 31 Mar 24 | 2,145 | 315 | 363 | 0 |
| 31 Mar 23 | 353 | 84 | 52 | 0 |
| 31 Mar 22 | 142 | 10 | 29 | 0 |
Quality Earnings: 544319 has a high level of non-cash earnings.
Growing Profit Margin: 544319's current net profit margins (14%) are lower than last year (14.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 544319's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 544319's past year earnings growth to its 5-year average.
Earnings vs Industry: 544319 earnings growth over the past year (86.2%) exceeded the Pharmaceuticals industry 20.7%.
Return on Equity
High ROE: 544319's Return on Equity (7.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 02:02 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senores Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |